Unknown

Dataset Information

0

BikDDA, a mutant of Bik with longer half-life expression protein, can be a novel therapeutic gene for triple-negative breast cancer.


ABSTRACT: Our previous studies showed that BikDD, a constitutively active mutant form of Bik, exhibited powerful antitumor effects in preclinical pancreatic, lung and breast cancer models. Howerver, the antitumor activity of BikDD in triple-negative breast cancer (TNBC) is unknown. Here we show that aberrant expression of p-ERK1/2 was a meaningful molecular phenotype in TNBC patients, and can be an obstacle for treatment because of the converse correlation with Bik. A novel mutant, BikDDA, in which Ser124 was changed to Alanine to block BikDD phosphorylation by p-ERK1/2 prevented subsequent ubiquitin-proteasome degradation. BikDDA showed a prolonged half-life and enhanced pro-apoptotic ability in TNBC cells compared with BikDD. Moreover, aberrant expression of p-ERK1/2 was associated with 5-fluorouracil resistance in breast cancer patients and BikDDA enhanced the therapeutic effects of 5-fluorouracil in vitro.

SUBMITTER: Jiao S 

PROVIDER: S-EPMC3956915 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC5085278 | biostudies-literature
| S-EPMC9241294 | biostudies-literature
| S-EPMC5502951 | biostudies-literature
| S-EPMC4494913 | biostudies-literature
| S-EPMC3265248 | biostudies-literature
| S-EPMC6173360 | biostudies-literature
| S-EPMC6537044 | biostudies-literature
| S-EPMC5688137 | biostudies-literature
| S-EPMC6046102 | biostudies-literature
| S-EPMC8581040 | biostudies-literature